EFFECTS OF A SELECTIVE PARTIAL D1 AGONIST, CY 208-243, IN DENOVO PATIENTS WITH PARKINSON DISEASE

被引：43

作者：

EMRE, M

RINNE, UK

RASCOL, A

LEES, A

AGID, Y

LATASTE, X

机构：

[1] Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel

[2] Department of Neurology, University of Turku

[3] Service de Neurologie, Hôpital Purpan, Toulouse

[4] National Hospital for Nervous Diseases, London

[5] Hcpital de la Salpêtrière, Paris

来源：

MOVEMENT DISORDERS | 1992年 / 7卷 / 03期

关键词：

PARKINSON DISEASE; DOPAMINE AGONISTS; D1-RECEPTOR AGONISTS;

D O I：

10.1002/mds.870070309

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A selective dopamine D1-receptor agonist, CY 208-243, was administered to 23 de novo patients who had had Parkinson disease (PD) for less-than-or-equal-to 3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2-receptor agonist, bromocriptine. Results showed that CY 208-243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine less-than-or-equal-to 15 mg to CY 208-243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1-receptor stimulation may result in improvement of motor disability in PD.

引用

页码：239 / 243

页数：5

共 7 条

[1]

Markstein R, Seiler MP, Vigouret JM, Urwyler S, Enz A, Dixon K., Pharmacologic properties of CY 208‐243, a novel D‐1 agonist, Progress in catecholamine research, part B: central aspects, pp. 59-64, (1988)

[2]

LeWitt PA, Galloway MP., Implications of D‐1 agonism for antiparkinsonian therapeutics, Recent developments in Parkinson's disease, 2, pp. 75-89, (1987)

[3]

Temlett JA, Quinn NP, Jenner PG, Et al., Antiparkinson activity of CY 208‐243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease, Movement Disorders, 4, pp. 261-265, (1989)

[4]

Nomoto M, Jenner PG, Marsden CD., The dopamine D‐2 agonist LY 141865, but not the D‐1 agonist SKF 38393, reverses parkinsonism induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in the common marmoset, Neurosci Lett, 57, pp. 37-41, (1985)

[5]

Tsui JKC, Wolters, Peppard RF, Calne DB., A doubleblind, placebo‐controlled, dose‐ranging study to investigate the safety and efficacy of CY 208‐243 in patients with Parkinson's disease, Neurology, 39, pp. 856-858, (1989)

[6]

Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase T., Selective D‐1 dopamine receptor agonist treatment of Parkinson's disease, J Neural Transm, 68, pp. 41-50, (1987)

[7]

Durrieu G, Senard JM, Rascol O, Et al., Blood pressre and plasma catecholamines in never‐treated parkinsonian patients: effect of a selective D‐1 agonist (CY 208‐243), Neurology, 40, pp. 707-709, (1990)

← 1 →